Skip to main content

IVERIC bio, Inc.

ISEEDelisted Jul 11, 2023
Industry
Pharmaceutical Preparations
SEC CIK
0001410939

IVERIC bio, Inc. was delisted on Jul 11, 2023; its insiders filed their last Form 4 on Jul 13, 2023; 256 institutions reported holding it in 13F filings for Q2 2023, worth $5.33B in total; Soros Fund Management was the only superinvestor holding it.

Key figures

Market cap
–
Not available
Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
256
Q2 2023, +33 vs. previous quarter
13F value
$5.33B
Reported value at the end of Q2 2023
Superinvestors holding
1
At the end of Q2 2023

From SEC filings, in USD.

Revenue, FY2022
–
No comparable prior period
Net income, FY2022
-$185.2M
No comparable prior period
Free cash flow, FY2022
-$164.5M
No comparable prior period
Revenue, Q1 FY2023
–
No comparable prior period

Superinvestors holding ISEE, Q2 2023

Go to the superinvestors tab

1 superinvestor reports holding IVERIC bio, Inc. on Form 13F. Percentages are the stock's share of each portfolio.

Soros Fund Management

George Soros

1.5%

IVERIC bio, Inc.'s share of the portfolio

Shares
1,700,001
Value
$66.9M

Latest insider trades

See all insider trades

Open-market purchases and sales by IVERIC bio, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 6, 2023 (view filing)Jul 33 daysWestby KeithSVP, Chief Operating OfficerSSale−20.0K$39.45−$789.0K−33.5%39.7K after10b5-1
Jun 6, 2023 (view filing)Jun 24 daysWestby KeithSVP, Chief Operating OfficerSSale−20.0K$37.87−$757.4K−33.5%39.7K after10b5-1
May 3, 2023 (view filing)May 1-22 daysWestby KeithSVP, Chief Operating OfficerSSale−40.0K$37.47−$1.50M−50.2%39.7K after3 lots10b5-1
May 3, 2023 (view filing)May 12 daysCarroll David FrancisSVP, Chief Financial OfficerSSale−63.5K$37.04−$2.35M−48.1%68.5K after10b5-1
Apr 25, 2023 (view filing)Apr 21-244 daysCarroll David FrancisSVP, Chief Financial OfficerSSale−50.0K$30.20−$1.51M−42.2%68.5K after2 lots10b5-1
Apr 25, 2023 (view filing)Apr 21-244 daysWestby KeithSVP, Chief Operating OfficerSSale−20.0K$30.07−$601.3K−33.5%39.7K after2 lots10b5-1
Apr 5, 2023 (view filing)Apr 32 daysWestby KeithSVP, Chief Operating OfficerSSale−40.0K$26.70−$1.07M−50.2%39.7K after2 lots10b5-1
Mar 6, 2023 (view filing)Mar 24 daysWestby KeithSVP, Chief Operating OfficerSSale−20.0K$23.93−$478.6K−33.5%39.7K after2 lots
Feb 22, 2023 (view filing)Feb 175 daysWestby KeithSVP, Chief Operating OfficerSSale−15.0K$25.05−$375.8K−24.4%46.4K after2 lots
Feb 3, 2023 (view filing)Feb 1-22 daysWestby KeithSVP, Chief Operating OfficerSSale−40.0K$23.43−$937.0K−46.3%46.4K after2 lots

Top 10 13F holders, Q2 2023

See all 256 holders

The largest institutional positions in IVERIC bio, Inc. at the end of Q2 2023; share changes are against Q1 2023.

Institutions holding ISEE in Q2 2023
InstitutionSharesValue% of portfolioChange in sharesAction
Vanguard Group Inc13,678,616$538.1M0.01%+17,227+0.1%Added
BlackRock Inc.10,789,526$424.5M0.01%+661,051+6.5%Added
Avoro Capital Advisors LLC8,050,000$316.7M4.30%+1,250,000+18.4%Added
UBS Oconnor LLC5,850,120$230.1M4.87%+5,850,120New
Beryl Capital Management LLC5,339,518$210.1M64.81%+5,339,518New
State Street Corp4,677,893$184.0M0.01%−946,285−16.8%Reduced
Goldman Sachs Group Inc4,222,280$166.1M0.04%+3,225,818+323.7%Added
Millennium Management LLC3,959,870$155.8M0.17%+2,719,573+219.3%Added
Deutsche Bank AG3,192,342$125.6M0.07%+1,910,414+149.0%Added
TIG Advisors, LLC2,904,364$114.3M6.88%+2,904,364New

1 member of Congress reported 2 trades in IVERIC bio, Inc. since 2020. Newest filings:

  1. Chris Jacobs

    House · NY · Nov 16, 2022

    Buy$1K-$15K

  2. Chris Jacobs

    House · NY · Sep 9, 2022

    Buy$1K-$15K